Weekly round-up #264
Register Today - Development of recombinant BCG Vaccine for tuberculosis utilizing Major Membrane Protein-II (MMP-II) antigen
In this talk, Dr Yumiko Tsikamoto will discuss her innovative research which has led to the development of a recombinant BCG vaccine against Mycobacterium tuberculosis. This novel vaccine features MTB-derived MMP-II and has been further modified by depleting the UreC gene, which stimulates phagosome-lysosome fusion in host cells infected with the recombinant BCG. Yimko will discus results from in vivo experiments that used a mouse model and show that this vaccine inhibits the multiplication of M. tuberculosis in the lungs much more efficiently than the traditional host BCG.
The Seminar will take place at 15:00GMT, 29 June 2023. Find out more and register today - www.validate-network.org/event/recombinant-bcg-vaccine-for-tb
Get Involved - WGNV Pipeline Sample Text
The Stop TB Partnership Working Group on New TB Vaccines (WGNV) is expanding its online TB Vaccine Pipeline to include vaccine candidates in preclinical research, from the proof-of-concept in animal models stage to preparing for first-in-human trials. If you are working on a candidate in preclinical development, please consider submitting information about the candidate for this Pipeline, and/or share the Preclinical Pipeline submission form with others involved in preclinical research.
- Global Infectious Diseases Scholars Program - Early Career Research Scientist Opportunity for Biomedical Scientist having prior Postdoctoral Experience - deadline 15 June 2023
- UKRI cross research council responsive mode pilot scheme - Funding for interdisciplinary ideas that transcend, combine or significantly span disciplines - deadline 4 July 2023
- UKRI Future Leaders Fellowships - Round 8 - £900 million fund that is helping to establish the careers of world-class research and innovation leaders across UK business and academia - deadline 4 July 2023
Find a full list of all relevant external funding on our our external funding page.
Training Opportunities and Events:
- BSI Midlands Immunology Group Symposium 2023, College Court Conference Centre, Leicester, UK, 8 June 2023
- FOCIS 2023 Annual Meeting, Boston, MA, USA, 20 - 23 June 2023
- FOCIS European Advanced Course and Conference on Immunology, Rouen, France, 27- 31 August 2023
Find more event opportunities on our Training and Events pages.
- Post-doctoral Research Assistant, Royal Veterinary College, Hertfordshire, UK, deadline 18 May 2023
- Professor in Infectious Diseases, University of Keele, UK, Deadline 23 May 2023
Other relevant career opportunities are on our jobs page.
- Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: a nationwide retrospective cohort study, Hwan Kim J et al, in Journal of Microbiology, Immunology and Infection
- Live attenuated Leishmania infantum centrin deleted mutant (LiCen-/-) as a novel vaccine candidate: A field study on safety, immunogenicity, and efficacy against canine leishmaniasis, Zarei Z et al, in Comparative Immunology
- Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control, Swanson R et al, in Nature Immunology
Check out our Publications Page for members' publications and email VALIDATE@ndm.ox.ac.uk if you have a paper you would like us to include.
Highlights on Twitter this week:
Pharma Times reported on a study showing BCG actually increased COVID-19 risk in some populations, Thai and US researchers are teaming up to develop a TB Vaccine, and New-Medical reported on the possibility that BCG could prevent COVID-19. APB Live and Himachal reported on World Immunization Week. A new study shows that BCG does not protect against COVID, Nature reported on making computational tools more accessible, and the Stop TB Partnership executive director shared a video message. Keep up to date with all the relevant news and opportunities by following @NetworkVALIDATE on Twitter.
Published: 3 May 2023
